ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 201

Identification of Patients with Rheumatoid Arthritis Treated with Biologics Using Standardized Vocabularies

Runsheng Wang1, Thomas Falconer 2 and George Hripcsak 2, 1Columbia University Medical Center, Division of Rheumatology, New York City, 2Columbia University Medical Center, Department of Biomedical Informatics, New York City

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: rheumatoid arthritis (RA) and epidemiologic methods

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: Epidemiology & Public Health Poster I: RA

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: To improve efficiency and transportability of observational research, common data models have been developed and maintained to translate data from source vocabularies into standardized vocabularies using vocabulary mapping.  The accuracy of mapping International Classification Codes to Systematized Nomenclature of Medicine — Clinical Terms (SNOMED-CT) of rheumatoid arthritis (RA) has been examined at the cohort level, however, its accuracy, in combination with standardized medication coding system RxNorm, has never been examined at the patient level.  The objective of this study is to examine the positive predictive value (PPV) of identifying patients with rheumatoid arthritis treated with biologics using Observational Medical Outcomes Partnership (OMOP) common data model.

Methods: NewYork-Presbyterian/Columbia University Irving Medical Center (NYP/CUIMC) EHR has been translated and maintained in OMOP common data model.  We searched NYP/CUIMC clinical data warehouse for prevalent cases of patients with rheumatoid arthritis treated with biologics using standardized codes for RA and biologics from 01/01/2013 to 12/31/2018, and excluded patients with other potential indications for biologics.  We randomly selected 100 patients from the search result for chart review.  We used documentation of a diagnosis of rheumatoid arthritis and a biologics at the index date (+/-4 days) as the gold standard.  For patients who had rheumatology visit notes, we examined whether they fulfilled 2010 Rheumatoid Arthritis Classification Criteria. 

Results: One hundred and two medical records were identified, and 11 were not accessible.  Among the 91 records that were retrieved and examined, 77 patients (84.6%) had a documented RA diagnosis and prescription of biologics, by either rheumatology providers or non-rheumatology providers.  Four patients did not have a documented diagnosis of RA, and ten did not have a documented use of biologics.  Of the 47 patients who had rheumatology visits, 41 (87.2%) fulfilled the 2010 RA classification criteria.

Conclusion: Using OMOP common data model and standardized vocabularies, we can identify RA patients treated with biologics with a PPV of 84.6% in a single center EHR system.


Disclosure: R. Wang, None; T. Falconer, None; G. Hripcsak, None.

To cite this abstract in AMA style:

Wang R, Falconer T, Hripcsak G. Identification of Patients with Rheumatoid Arthritis Treated with Biologics Using Standardized Vocabularies [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/identification-of-patients-with-rheumatoid-arthritis-treated-with-biologics-using-standardized-vocabularies/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identification-of-patients-with-rheumatoid-arthritis-treated-with-biologics-using-standardized-vocabularies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology